Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31058043 | 1.00 | POLB (0.47) | POLBL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL4930058 | 0.83 | POLB (0.44) | POLBL3MBTL1RAB9AKMT2ALMNA | |
| SCHEMBL1118465 | 0.80 | POLB (0.44) | POLBL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL31058272 | 0.80 | POLB (0.44) | POLBL3MBTL1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30602334 | 0.80 | ALDH1A1 (0.43) | KMT2AMEN1SMN1; SMN2LMNAHPGD | |
| SCHEMBL1118449 | 0.79 | HTR2A (0.43) | POLBL3MBTL1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL4334230 | 0.79 | POLB (0.61) | POLBL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL30231962 | 0.78 | POLB (0.52) | POLBL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL1118653 | 0.78 | POLB (0.52) | POLBL3MBTL1RAB9AKMT2AMEN1 | |
| SCHEMBL1118636 | 0.78 | POLB (0.52) | POLBL3MBTL1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161289-A1 | KAT6 Targeting Compounds | PRELUDE THERAPEUTICS INCORPORATED | 2025-05-22 | — | — | US | disclosed |
| WO-2025101942-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4539937-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | Prelude Therapeutics Incorporated (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023245150-A9 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | PRELUDE THERAPEUTICS, INCORPORATED | 2023-12-28 | — | — | US | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023245150-A1 | KAT6 TARGETING COMPOUNDS WITH UBIQUITIN LIGASE BINDING MOIETY | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-12-21 | — | — | WO | disclosed |
| US-8378092-B2 | Chlorothiophene-amides as inhibitors of coagulation factors Xa and thrombin | SANOFI (FR) | 2013-02-19 | — | — | US | disclosed |
| EP-2254881-B1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | SANOFI SA (FR) | 2012-09-12 | — | — | EP | disclosed |
| US-20110112075-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-2254881-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | Sanofi-Aventis (FR) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009103440-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | SANOFI-AVENTIS (FR) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416240-A1 | KAT6 TARGETING COMPOUNDS | KAT6A, KAT6B, KAT2A | POLB 1282/4885L3MBTL1 394/4885RAB9A 2893/4885 |
| US-20110112075-A1 | CHLOROTHIOPHENE-AMIDES AS INHIBITORS OF COAGULATION FACTORS XA AND THROMBIN | F12, F3, F2 | POLB 3017/4885L3MBTL1 727/4885RAB9A 2937/4885 |
| US-20250161289-A1 | KAT6 Targeting Compounds | KAT6A, KAT6B, KAT2A | POLB 1282/4885L3MBTL1 394/4885RAB9A 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.